Komori
Daito Pharmaceutical (4577) · RiskMitigated

Risk of Dependence on Specific Suppliers and Procurement Difficulties

First written in FY2016. 2 of 4 entries say "Restated". Latest entry: FY2020.

4entries
5years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY20182016: 120162017: 120172018: 120182019: 020192020: 12020
Same theme, other companies
Concentrated dependence on specific suppliersA theme 102 companies write about · 102 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2020: 20 of 63 companies on the "Worse" side.

19 other companies' latest entry also says "Mitigated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 102 companies compared. The sentences above are computed from all 102.
Full recordFilings, disclosures and news, newest first
  1. FY2020MitigatedAnnual report

    「To address these risks, the Group is working to secure stable procurement of raw materials and products by considering and securing procurement channels through multiple sourcing.」

    As a measure addressing dependence on specific suppliers and procurement difficulty risk, it specifies securing procurement channels through multiple sourcing.
  2. FY2018RestatedAnnual report

    「The Group depends on certain business partners, including overseas companies, for the procurement of some raw materials and products and for outsourced processing. If disasters or other factors make it difficult to procure those raw materials or products or to conduct outsourced processing, forcing the Group to suspend the manufacture of important products or important procurement and sales transactions, its business performance and other results may be affected.」

    Continues to note the risks of dependence on specific suppliers and the suspension of procurement and outsourced processing due to disasters and other events.
  3. FY2017RestatedAnnual report

    「The Group depends on certain business partners, including overseas companies, for the procurement of some raw materials and products and for outsourced processing. If disasters or other factors make it difficult to procure those raw materials or products or to conduct outsourced processing, forcing the Group to suspend the manufacture of important products or important procurement and sales transactions, its business performance and other results may be affected.」

    Continues to note the risks of dependence on specific suppliers and the suspension of procurement and outsourced processing due to disasters and other events.
  4. FY2016First statedAnnual report

    「The Group depends on certain business partners, including overseas companies, for the procurement of some raw materials and products and for outsourced processing」

    It notes the possibility that disasters and other events could result in the suspension of manufacturing of important products and the suspension of procurement and sales transactions.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Daito Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.